tiprankstipranks
Trending News
More News >
Micro-X Ltd. (AU:MX1)
ASX:MX1
Australian Market
Advertisement

Micro-X Ltd. (MX1) AI Stock Analysis

Compare
6 Followers

Top Page

AU:MX1

Micro-X Ltd.

(Sydney:MX1)

Rating:47Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Micro-X Ltd. is facing significant challenges with profitability and cash flow despite moderate revenue growth. The technical analysis shows positive short-term momentum, but potential overbuying is a concern. The lack of profitability and dividend yield further detracts from the valuation appeal.

Micro-X Ltd. (MX1) vs. iShares MSCI Australia ETF (EWA)

Micro-X Ltd. Business Overview & Revenue Model

Company DescriptionMicro-X Limited designs, develops, and manufactures lightweight carbon nano tube-based X-ray products for the healthcare and security imaging markets in Australia. The company offers rover veterinary, a mobile X-ray machine to diagnose and treat animals for general veterinarian practices; Carestream DRX Revolution Nano, a mobile X-ray imaging machine used for high intensity workflow diagnostic medical imaging in hospitals; and IED X-ray cameras. It also provides miniature baggage scanners to detect hidden threats concealed within passenger carry-on luggage; airport screening reimagined, a passenger self-screening airport checkpoint; and brain CT scanners for use in road and air ambulances. The company was incorporated in 2011 and is based in Tonsley, Australia.
How the Company Makes MoneyMicro-X Ltd. generates revenue primarily through the sale of its portable x-ray imaging products. The company's revenue model is based on direct sales to hospitals, clinics, and medical facilities for diagnostic imaging, as well as sales to airports and security agencies for security screening purposes. Additionally, Micro-X engages in partnerships and contracts with defense organizations for military-grade imaging solutions. The company's earnings are supported by continuous innovation in its technology, strategic partnerships with healthcare providers and government agencies, and expansion into new markets and regions.

Micro-X Ltd. Financial Statement Overview

Summary
Micro-X Ltd. is experiencing growth in revenue but faces significant challenges in achieving profitability and positive cash flow. The balance sheet shows stability with a low leverage position, though profitability impacts return metrics.
Income Statement
45
Neutral
Micro-X Ltd. has shown a moderate revenue growth rate of 1.45% over the past year, reflecting a slight improvement. However, the company is still facing challenges in terms of profitability, with negative net and gross profit margins. The EBIT and EBITDA margins are also negative, indicating operational difficulties in achieving profitable growth.
Balance Sheet
55
Neutral
The company has a relatively low debt-to-equity ratio of 0.28, suggesting conservative leverage, which is a positive. However, the return on equity is negative due to net losses, indicating inefficiencies in generating returns from shareholders' equity. The equity ratio of 53.03% highlights a stable capital structure with a significant portion of assets financed by equity.
Cash Flow
40
Negative
Micro-X Ltd. shows negative free cash flow growth, highlighting ongoing challenges in generating positive cash flow. The operating cash flow to net income ratio is negative, indicating struggles in converting operations into cash. However, the company has managed to secure financing, which provides some liquidity support.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue15.22M15.01M8.97M3.77M4.25M
Gross Profit5.74M-7.11M-12.33M-12.96M-7.69M
EBITDA-14.35M-14.71M-19.02M-13.61M-9.29M
Net Income-9.77M-10.75M-17.09M-14.73M-10.07M
Balance Sheet
Total Assets26.89M30.30M31.28M44.68M33.70M
Cash, Cash Equivalents and Short-Term Investments3.23M5.22M10.30M30.14M18.32M
Total Debt3.99M4.77M5.38M5.90M13.54M
Total Liabilities12.63M13.17M12.05M10.53M18.96M
Stockholders Equity14.26M17.13M19.22M34.15M14.74M
Cash Flow
Free Cash Flow-6.80M-11.77M-19.22M-10.76M-11.65M
Operating Cash Flow-6.43M-10.99M-18.11M-9.86M-9.46M
Investing Cash Flow-369.00K-779.00K-1.11M-901.00K-2.20M
Financing Cash Flow4.81M6.69M-612.00K22.57M28.37M

Micro-X Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.06
Price Trends
50DMA
0.05
Positive
100DMA
0.06
Positive
200DMA
0.07
Negative
Market Momentum
MACD
<0.01
Negative
RSI
58.26
Neutral
STOCH
60.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MX1, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.26 is Neutral, neither overbought nor oversold. The STOCH value of 60.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MX1.

Micro-X Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.39B5.75-7.44%3.10%11.55%-28.15%
54
Neutral
AU$52.83M-7.59%28.89%72.95%
51
Neutral
AU$153.50M-58.61%-74.88%
48
Neutral
AU$11.78M-98.08%-7.44%30.34%
47
Neutral
AU$43.37M-135.33%-27.58%33.69%
46
Neutral
AU$111.73M-52.37%471.29%-4.58%
41
Neutral
AU$119.47M-35.20%4.68%-155.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MX1
Micro-X Ltd.
0.06
-0.02
-25.00%
AU:CYC
Cyclopharm Limited
1.02
-0.53
-34.19%
AU:CSX
CleanSpace Holdings Ltd.
0.68
0.26
61.90%
AU:EMV
EMvision Medical Devices Ltd.
1.80
-0.22
-10.89%
AU:CBL
Control Bionics Ltd.
0.04
-0.01
-20.00%
AU:4DX
4DMedical Ltd
0.24
-0.27
-52.94%

Micro-X Ltd. Corporate Events

Micro-X Ltd Achieves Key Development Milestones in Health and Security Projects
Jun 17, 2025

Micro-X Ltd has successfully achieved significant development milestones on time and within budget for its contracts with ARPA-H and Billion Prima, enhancing its position in the health and security markets. The company completed Milestone 3 for a Full Body CT scanner under its ARPA-H contract and Milestone 2 for a baggage and parcel scanning unit with Billion Prima. These achievements underscore Micro-X’s commitment to timely project delivery and its strategic partnerships, which are crucial for its growth and market expansion.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.21 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Appoints New Company Secretary to Enhance Growth
May 30, 2025

Micro-X Ltd. has announced the appointment of Mr. Richard Willson as the new Company Secretary, effective May 30, 2025. Mr. Willson brings over 25 years of experience in the technology and resources sectors, with a strong background in corporate governance and financial management. This strategic appointment is expected to strengthen Micro-X’s corporate governance and support its growth ambitions in the health and security markets. The company continues to innovate in x-ray technology and expand its market presence, with significant projects underway in both healthcare and security sectors.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.21 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Announces Quotation of New Securities on ASX
May 14, 2025

Micro-X Ltd. has announced the quotation of 171,819 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code MX1, effective from May 15, 2025. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.21 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Director Increases Stake Through Share Placement
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Patrick O’Brien acquiring 1,428,571 ordinary shares, increasing his total holdings to 10,287,591 shares. This acquisition was made through a company placement approved by shareholders, reflecting confidence in the company’s strategic direction and potential growth, which could impact stakeholders positively by enhancing market confidence.

Micro-X Director Increases Stake with Significant Share Acquisition
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Ilona Meyer acquiring 357,143 ordinary shares through a company placement approved by shareholders. This acquisition increases Meyer’s total holdings to 567,961 fully paid ordinary shares, indicating a significant investment in the company’s future, potentially impacting its market positioning and stakeholder confidence.

Micro-X Director Increases Stake, Signaling Confidence in Growth
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Jim McDowell acquiring 714,286 ordinary shares through the company’s placement approved at the Extraordinary General Meeting in April 2025. This acquisition increases McDowell’s indirect holding, indicating a vote of confidence in the company’s strategic direction and potential growth, which could positively impact stakeholders and market perception.

Micro-X Director Increases Stake with Share Acquisition
May 8, 2025

Micro-X Ltd. announced a change in the director’s interest, with Director Andrew Hartmann acquiring 357,143 fully paid ordinary shares valued at $25,000. This acquisition was part of a company placement approved by shareholders, potentially strengthening the director’s alignment with company interests and signaling confidence in Micro-X’s future growth.

Micro-X Ltd. Announces Quotation of New Securities on ASX
May 7, 2025

Micro-X Ltd. has announced the quotation of 2,857,143 ordinary fully paid securities on the Australian Securities Exchange (ASX) with the code MX1, set to be issued on May 8, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025